KCNQ2 Antibody (F-3): sc-365115
- KCNQ2 Antibody (F-3) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against amino acids 641-780 mapping near the C-terminus of KCNQ2 of human origin
- recommended for detection of KCNQ2 of human origin by WB, IP, IF and ELISA
- m-IgGκ BP-HRP is the preferred secondary detection reagent for KCNQ2 Antibody (F-3) for WB applications. This reagent is now offered in a bundle with KCNQ2 Antibody (F-3) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
QUICK LINKS
SEE ALSO...
KCNQ2 Antibody (F-3) is a mouse monoclonal IgG1 antibody that detects KCNQ2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). KCNQ2 is a voltage-gated potassium channel that plays a crucial role in regulating neuronal excitability and maintaining the resting membrane potential, which is vital for proper electrical signaling in the brain. Mutations in the KCNQ2 gene can lead to benign familial neonatal convulsions, a form of epilepsy characterized by recurrent seizures in infants. KCNQ2 is composed of six transmembrane domains, forming a channel that allows potassium ions to flow across the cell membrane, thereby influencing neuronal firing rates and overall brain activity. Understanding the structure and function of KCNQ2 is essential for developing targeted therapies for epilepsy and other neurological disorders, as KCNQ2 highlights the importance of potassium channels in maintaining the balance of excitatory and inhibitory signals in the central nervous system. Anti-KCNQ2 antibody (F-3) is an invaluable tool for researchers studying the molecular mechanisms underlying epilepsy and neuronal function.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
KCNQ2 Antibody (F-3) References:
- FGF14 is a regulator of KCNQ2/3 channels. | Pablo, JL. and Pitt, GS. 2017. Proc Natl Acad Sci U S A. 114: 154-159. PMID: 27994149
- Epilepsy-Associated KCNQ2 Channels Regulate Multiple Intrinsic Properties of Layer 2/3 Pyramidal Neurons. | Niday, Z., et al. 2017. J Neurosci. 37: 576-586. PMID: 28100740
- KCNQ2 Epileptic Encephalopathy in Early Infancy. | Kasinathan, A., et al. 2017. Indian J Pediatr. 84: 877-878. PMID: 28631195
- Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. | Kuersten, M., et al. 2020. Eur J Med Genet. 63: 103628. PMID: 30771507
- Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy. | Goto, A., et al. 2019. Epilepsia. 60: 1870-1880. PMID: 31418850
- KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. | Miceli, F., et al. 2022. EBioMedicine. 81: 104130. PMID: 35780567
- Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy. | Yang, GM., et al. 2023. Acta Pharmacol Sin. 44: 1589-1599. PMID: 36932231
- Relationship Between Epileptic Activity and Developmental Outcome in KCNQ2-Related Epilepsy. | Casas-Alba, D., et al. 2023. Pediatr Neurol. 144: 11-15. PMID: 37099824
- KCNQ2 channels regulate the population activity of neonatal GABAergic neurons ex vivo. | Hou, B., et al. 2023. Front Neurol. 14: 1207539. PMID: 37409016
- Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism. | Nissenkorn, A., et al. 2024. Front Cell Neurosci. 18: 1380442. PMID: 39175503
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KCNQ2 Antibody (F-3) | sc-365115 | 200 µg/ml | $316.00 | |||
KCNQ2 Antibody (F-3): m-IgGκ BP-HRP Bundle | sc-535152 | 200 µg Ab; 40 µg BP | $354.00 |